Researchers from the Universitat Politècncia de Catalunya (UPC) and ABAC Therapeutics collaborate to develop new compounds and molecules designed to selectively attack bacteria resistant to current antibiotics. The new drugs will be respectful of the human bacterial flora making possible to combat the resistance of some of these pathogens «using an innovative approach» based on precision medicine.
This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.